D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders

Abstract

The present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of central nervous system disorders.

We claim: 
     
         1 . A method for the alleviation of central nervous system disorders caused by a deficit in N-methyl-D-aspartate receptor function, the method comprising administering to a subject in need thereof an acceptable pharmaceutical composition containing a therapeutically effective amount of one or more D-serine transporter inhibitor compounds. 
     
     
         2 . The method, according to  claim 1 , further comprising administering to a subject in need thereof an acceptable pharmaceutical composition containing a therapeutically effective amount of one or more D-serine transporter inhibitor compounds selected from the Glycine/Alanine family, the Glutamine/Asparagine family, the Tryptophan Family, the Phenylglycine family, the Phenylalanine family, the Cysteine family, the Serine/Threonine family, the Cyclic Amino Acid family and the Proline family. 
     
     
         3 . The method, according to  claim 2 , further comprising administering to a subject in need thereof an acceptable pharmaceutical composition containing a therapeutically effective amount of one or more D-serine transporter inhibitor compounds selected from L-gamma-glutamyl-4-nitroanilide, L-4-hydroxyphenylglycine, L-4-fluorophenylglycine, L-phenylglycine, trans-4-hydroxy-L-proline and R-gamma-2,4-dichlorobenzyl-L-proline. 
     
     
         4 . The method, according to  claim 3 , comprising administering to a subject in need thereof an acceptable pharmaceutical composition containing a therapeutically effective amount of L-gamma-glutamyl-4-nitroanilide. 
     
     
         5 . The method, according to  claim 3 , comprising administering to a subject in need thereof an acceptable pharmaceutical composition containing a therapeutically effective amount of L-4-hydroxyphenylglycine. 
     
     
         6 . The method, according to  claim 3 , comprising administering to a subject in need thereof an acceptable pharmaceutical composition containing a therapeutically effective amount of L-4-fluorophenylglycine. 
     
     
         7 . The method, according to  claim 3 , comprising administering to a subject in need thereof an acceptable pharmaceutical composition containing a therapeutically effective amount of L-phenylglycine. 
     
     
         8 . The method, according to  claim 3 , comprising administering to a subject in need thereof an acceptable pharmaceutical composition containing a therapeutically effective amount of trans-4-hydroxy-L-proline. 
     
     
         9 . The method, according to  claim 3 , comprising administering to a subject in need thereof an acceptable pharmaceutical composition containing a therapeutically effective amount of R-gamma-2,4-dichlorobenzyl-L-proline.